143 related articles for article (PubMed ID: 38625642)
1. Lifileucel: First Approval.
Keam SJ
Mol Diagn Ther; 2024 May; 28(3):339-344. PubMed ID: 38625642
[TBL] [Abstract][Full Text] [Related]
2. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
Sarnaik AA; Hamid O; Khushalani NI; Lewis KD; Medina T; Kluger HM; Thomas SS; Domingo-Musibay E; Pavlick AC; Whitman ED; Martin-Algarra S; Corrie P; Curti BD; Oláh J; Lutzky J; Weber JS; Larkin JMG; Shi W; Takamura T; Jagasia M; Qin H; Wu X; Chartier C; Graf Finckenstein F; Fardis M; Kirkwood JM; Chesney JA
J Clin Oncol; 2021 Aug; 39(24):2656-2666. PubMed ID: 33979178
[TBL] [Abstract][Full Text] [Related]
3. Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) - Lifileucel (Amtagvi).
Parums DV
Med Sci Monit; 2024 May; 30():e944927. PubMed ID: 38689550
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
Chesney J; Lewis KD; Kluger H; Hamid O; Whitman E; Thomas S; Wermke M; Cusnir M; Domingo-Musibay E; Phan GQ; Kirkwood JM; Hassel JC; Orloff M; Larkin J; Weber J; Furness AJS; Khushalani NI; Medina T; Egger ME; Graf Finckenstein F; Jagasia M; Hari P; Sulur G; Shi W; Wu X; Sarnaik A
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600653
[TBL] [Abstract][Full Text] [Related]
5. Lifileucel: the first cellular therapy approved for solid tumours.
Julve M; Lythgoe MP; Larkin J; Furness AJS
Trends Cancer; 2024 Jun; 10(6):475-477. PubMed ID: 38724322
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab: first global approval.
Poole RM
Drugs; 2014 Oct; 74(16):1973-1981. PubMed ID: 25331768
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
Nguyen LT; Saibil SD; Sotov V; Le MX; Khoja L; Ghazarian D; Bonilla L; Majeed H; Hogg D; Joshua AM; Crump M; Franke N; Spreafico A; Hansen A; Al-Habeeb A; Leong W; Easson A; Reedijk M; Goldstein DP; McCready D; Yasufuku K; Waddell T; Cypel M; Pierre A; Zhang B; Boross-Harmer S; Cipollone J; Nelles M; Scheid E; Fyrsta M; Lo CS; Nie J; Yam JY; Yen PH; Gray D; Motta V; Elford AR; DeLuca S; Wang L; Effendi S; Ellenchery R; Hirano N; Ohashi PS; Butler MO
Cancer Immunol Immunother; 2019 May; 68(5):773-785. PubMed ID: 30747243
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.
Kakavand H; Wilmott JS; Menzies AM; Vilain R; Haydu LE; Yearley JH; Thompson JF; Kefford RF; Hersey P; Long GV; Scolyer RA
Clin Cancer Res; 2015 Jul; 21(14):3140-8. PubMed ID: 25609064
[TBL] [Abstract][Full Text] [Related]
9. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
[TBL] [Abstract][Full Text] [Related]
10. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
11. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
[TBL] [Abstract][Full Text] [Related]
12. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
[TBL] [Abstract][Full Text] [Related]
13. Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.
Bjoern J; Lyngaa R; Andersen R; Hölmich LR; Hadrup SR; Donia M; Svane IM
Oncotarget; 2017 Apr; 8(16):27062-27074. PubMed ID: 28423678
[TBL] [Abstract][Full Text] [Related]
14. Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?
Svane IM; Verdegaal EM
Cancer Immunol Immunother; 2014 Oct; 63(10):1081-91. PubMed ID: 25099366
[TBL] [Abstract][Full Text] [Related]
15. Lifileucel (Amtagvi): A cellular therapy for melanoma.
Med Lett Drugs Ther; 2024 Apr; 66(1701):e77-e78. PubMed ID: 38691651
[No Abstract] [Full Text] [Related]
16. Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma.
Seitter SJ; Sherry RM; Yang JC; Robbins PF; Shindorf ML; Copeland AR; McGowan CT; Epstein M; Shelton TE; Langhan MM; Franco Z; Danforth DN; White DE; Rosenberg SA; Goff SL
Clin Cancer Res; 2021 Oct; 27(19):5289-5298. PubMed ID: 34413159
[TBL] [Abstract][Full Text] [Related]
17. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
18. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.
Kakavand H; Rawson RV; Pupo GM; Yang JYH; Menzies AM; Carlino MS; Kefford RF; Howle JR; Saw RPM; Thompson JF; Wilmott JS; Long GV; Scolyer RA; Rizos H
Clin Cancer Res; 2017 Oct; 23(20):6054-6061. PubMed ID: 28724663
[No Abstract] [Full Text] [Related]
20. Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.
Patrinely JR; Baker LX; Davis EJ; Song H; Ye F; Johnson DB
Cancer; 2020 Aug; 126(15):3448-3455. PubMed ID: 32463489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
